Open AccessDid Osteoblastic Cell Therapy Improve the Prognosis of Pre-fracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial
Author(s) -
JeanPhilippe Hauzeur,
Chantal Lechanteur,
Étienne Baudoux,
Viviane De Maertelaer,
Sanjiva Pather,
R. Katz,
Michel Malaise,
Julia Ino,
Yves Béguin
Publication year - 2019
Publication title -
clinical orthopaedics and related research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.178
H-Index - 204
eISSN - 1528-1132
pISSN - 0009-921X
DOI - 10.1097/corr.0000000000001107
Subject(s) - medicine , femoral head , surgery , randomized controlled trial , stage (stratigraphy) , bone healing , bone marrow , paleontology , biology
In patients with nontraumatic osteonecrosis of the femoral head (ONFH), implantation of bone marrow aspirate concentrate (BMAC) could delay the progression of osteonecrosis and improve symptoms in pre-fracture ONFH. However, the BMAC content, especially in osteoblastic stem cells, could have an important individual variability. An autologous osteoblastic cell product could improve the effect of such cell-based therapy.